-
It achieved 12% full-year revenue growth even though 2025 was only the third time in 25 years that US injectables volumes declined.
-
He attributed Jeuveau’s 14% market share capture to a “beauty first” strategy that aligns with cash-based aesthetic practices rather than reimbursement models.
-
A new portfolio growth rebate program designed to incentivize accounts to consolidate their spend on toxins and fillers with Evolus was successfully piloted.
-
We expanded the Evolysse HA filler footprint to over 3,000 purchasing accounts, leveraging Cold-X technology to meet consumer demand for natural-looking results.
-
Executed a structural spending reset in mid-2025 to align the organization for durable, profitable growth and significant operating leverage.
-
International revenue nearly doubled year-over-year, driven by a transition to a direct model in Germany and near double-digit share in the UK.
-
Maintained brand resilience through Evolus Rewards, an SMS-based loyalty program that has grown to more than 1.4 million patients treated.
-
Project 2026 total net revenue between $327 million and $337 million, assuming a low-single-digit toxins market recovery and a low-single-digit fillers market decline.
-
Anticipating full-year 2026 profitability with low- to mid-single-digit adjusted EBITDA margins, supported by a largely flat non-GAAP operating expense base.
-
Planning European launch of Estyme in Q2 2026 and awaiting FDA approval of Evolysse Sculpt in Q4.
-
Initiate a large-scale sampling and experience program for Evolysse in Q2 2026 to broaden adoption ahead of the launch of the flagship Sculpt.
-
Reiterating 2028 targets of between $450 million and $500 million in revenue with adjusted EBITDA margins of 13% to 15% as the portfolio grows.
-
Implemented a new revolving credit facility that provides up to $40 million in liquidity to fund working capital and inventory for upcoming product launches.
-
He confirmed that Jeuveau is currently not affected by tariffs, while Evolysse is subject to an alleged 15% tariff in the 2026 guidance.
-
We transitioned the core profitability metric to Adjusted EBITDA beginning in 2026 to improve comparability with industry peers.
-
It expressed a clear intention to avoid raising equity capital, focusing instead on existing cash reserves and debt tranches to maintain value for shareholders.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our number one choice. Tap here.